SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Xu, Shuang Nian ^a   Wang, Tian Shi ^b   Li, Xi ^a   Wang, Yi Ping ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SIRT2 PROTEIN, HUMAN; SIRTUIN 2;

ACUTE MYELOID LEUKEMIA; CELL PROLIFERATION; GENE KNOCKDOWN; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; GLUCOSEPHOSPHATE DEHYDROGENASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; NADP; SIRTUIN 2;

EID: 84986252287     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32734     Document Type: Article

References (50)

1. Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21, 297-308, doi: 10. 1016/j. ccr. 2012. 02. 014 (2012).
2. Singh, S. R., Tan, M. & Rameshwar, P. Cancer metabolism: targeting metabolic pathways in cancer therapy. Cancer Lett. 356, 147-148, doi: 10. 1016/j. canlet. 2014. 06. 002 (2015).
3. Yang, H. B. et al. Acetylation of MAT IIalpha represses tumour cell growth and is decreased in human hepatocellular cancer. Nat. Commun. 6, 6973, doi: 10. 1038/ncomms7973 (2015).
4. Estey, E. & Dohner, H. Acute myeloid leukaemia. Lancet 368, 1894-1907, doi: 10. 1016/S0140-6736(06)69780-8 (2006).
5. Wouters, B. J. & Delwel, R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood 127, 42-52, doi: 10. 1182/blood-2015-07-604512 (2016).
6. Akers, L. J. et al. Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin. Leuk. Res. 35, 814-820, doi: 10. 1016/j. leukres. 2010. 12. 028 (2011).
7. Hulleman, E. et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 113, 2014-2021, doi: 10. 1182/blood-2008-05-157842 (2009).
8. Gottschalk, S., Anderson, N., Hainz, C., Eckhardt, S. G. & Serkova, N. J. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin. Cancer Res. 10, 6661-6668, doi: 10. 1158/1078-0432. CCR-04-0039 (2004).
9. Karnauskas, R. et al. Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo. Oncogene 22, 688-698, doi: 10. 1038/sj. onc. 1206159 (2003).
10. Saito, Y., Chapple, R. H., Lin, A., Kitano, A. & Nakada, D. AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow. Cell Stem Cell 17, 585-596, doi: 10. 1016/j. stem. 2015. 08. 019 (2015).
11. Meynet, O. et al. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis. Leukemia 26, 1145-1147, doi: 10. 1038/leu. 2011. 327 (2012).
12. Chen, Y. et al. Inhibition of pentose phosphate pathway suppresses acute myelogenous leukemia. Tumour Biol. 37, 6027-6034, doi: 10. 1007/s13277-015-4428-5 (2016).
13. Lowman, X. H. et al. The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. Mol. Cell 40, 823-833, doi: 10. 1016/j. molcel. 2010. 11. 035 (2010).
14. Yamamoto, T. et al. Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat. Commun. 5, 3480, doi: 10. 1038/ncomms4480 (2014).
15. Shan, C. et al. Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. Mol. Cell 55, 552-565, doi: 10. 1016/j. molcel. 2014. 06. 020 (2014).
16. Kuehne, A. et al. Acute Activation of Oxidative Pentose Phosphate Pathway as First-Line Response to Oxidative Stress in Human Skin Cells. Mol. Cell 59, 359-371, doi: 10. 1016/j. molcel. 2015. 06. 017 (2015).
17. Jiang, P. et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 13, 310-316, doi: 10. 1038/ncb2172 (2011).
18. Jiang, P., Du, W. & Wu, M. Regulation of the pentose phosphate pathway in cancer. Protein Cell 5, 592-602, doi: 10. 1007/s13238-014-0082-8 (2014).
19. Patra, K. C. & Hay, N. The pentose phosphate pathway and cancer. Trends Biochem. Sci. 39, 347-354, doi: 10. 1016/j. tibs. 2014. 06. 005 (2014).
20. Riganti, C., Gazzano, E., Polimeni, M., Aldieri, E. & Ghigo, D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic. Biol. Med. 53, 421-436, doi: 10. 1016/j. freeradbiomed. 2012. 05. 006 (2012).
21. Du, W. et al. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat. Cell Biol. 15, 991-1000, doi: 10. 1038/ncb2789 (2013).
22. Cappellini, M. D. & Fiorelli, G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 371, 64-74, doi: 10. 1016/S0140-6736(08)60073-2 (2008).
23. Leopold, J. A. et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13, 189-197, doi: nm1545 (2007).
24. Wang, Y. P. et al. Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO J. 33, 1304-1320, doi: 10. 1002/embj. 201387224 (2014).
25. Furuta, E., Okuda, H., Kobayashi, A. & Watabe, K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim. Biophys. Acta. 1805, 141-152, doi: 10. 1016/j. bbcan. 2010. 01. 005 (2010).
26. Batetta, B. et al. G6PD activity and gene expression in leukemic cells from G6PD-deficient subjects. Cancer Lett. 140, 53-58 (1999).
27. Bou Samra, E. et al. New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients. Br. J. Haematol. 157, 347-356, doi: 10. 1111/j. 1365-2141. 2012. 09069. x (2012).
28. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074, doi: 10. 1056/NEJMoa1301689 (2013).
29. Tian, W. N. et al. Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J. Biol. Chem. 273, 10609-10617 (1998).
30. Di Monaco, M. et al. Role of glucose-6-phosphate dehydrogenase inhibition in the antiproliferative effects of dehydroepiandrosterone on human breast cancer cells. Br. J. Cancer 75, 589-592 (1997).
31. Hecker, P. A., Leopold, J. A., Gupte, S. A., Recchia, F. A. & Stanley, W. C. Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 304, H491-H500, doi: 10. 1152/ajpheart. 00721. 2012 (2013).
32. Hong, X. et al. PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut 63, 1635-1647, doi: 10. 1136/gutjnl-2013-305302 (2014).
33. Cosentino, C., Grieco, D. & Costanzo, V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J. 30, 546-555, doi: 10. 1038/emboj. 2010. 330 (2011).
34. Rao, X. et al. O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth. Nat. Commun. 6, 8468, doi: 10. 1038/ncomms9468 (2015).
35. Xu, Y., Osborne, B. W. & Stanton, R. C. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am. J. Physiol. Renal Physiol. 289, F1040-F1047, doi: 00076. 2005 (2005).
36. Zhang, Z., Apse, K., Pang, J. & Stanton, R. C. High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J. Biol. Chem. 275, 40042-40047, doi: 10. 1074/jbc. M007505200 (2000).
37. Dong, L. H. et al. TRAF6-mediated SM22alpha K21 ubiquitination promotes G6PD activation and NADPH production, contributing to GSH homeostasis and VSMC survival in vitro and in vivo. Circ. Res. 117, 684-694, doi: 10. 1161/CIRCRESAHA. 115. 306233 (2015).
38. Wu, L. E. & Sinclair, D. A. SIRT2 controls the pentose phosphate switch. EMBO J. 33, 1287-1288, doi: 10. 15252/embj. 201488713 (2014).
39. Gomes, P., Outeiro, T. F. & Cavadas, C. Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism. Trends Pharmacol. Sci. 36, 756-768, doi: 10. 1016/j. tips. 2015. 08. 001 (2015).
40. Kleszcz, R., Paluszczak, J. & Baer-Dubowska, W. Targeting 41. Chalkiadaki, A. & Guarente, L. The multifaceted functions of sirtuins in cancer. Nat. Rev. Cancer 15, 608-624, doi: 10. 1038/nrc3985 (2015).
41. Rumpf, T. et al. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nat. Commun. 6, 6263, doi: 10. 1038/ncomms7263 (2015).
42. Jing, H. et al. A SIRT2-selective inhibitor promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity. Cancer Cell 29, 297-310, doi: 10. 1016/j. ccell. 2016. 02. 007 (2016).
43. Gao, X. et al. Acetate functions as an epigenetic metabolite to promote lipid synthesis under hypoxia. Nat. Commun. 7, 11960, doi: 10. 1038/ncomms11960 (2016).
44. Pallasch, C. P. et al. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia 22, 585-592, doi: 2405058 (2008).
45. Southam, A. D. et al. Drug redeployment to kill leukemia and lymphoma cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids. Cancer Res. 75, 2530-2540, doi: 10. 1158/0008-5472. CAN-15-0202 (2015).
46. Polimeni, M. et al. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem J. 439, 141-149, doi: 10. 1042/BJ20102016 (2011).
47. Zhou, X. et al. Targeted polyubiquitylation of RASSF1C by the Mule and SCFbeta-TrCP ligases in response to DNA damage. Biochem. J. 441, 227-236, doi: 10. 1042/BJ20111500 (2012).
48. Lei, Q. et al. NKX3. 1 stabilizes p53, inhibits AKT activation, blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9, 367-378, doi: S1535-6108(06)00118-8 (2006).
49. Lv, L. et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 42, 719-730, doi: 10. 1016/j. molcel. 2011. 04. 025 (2011).
50. Wang, Y. et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol. Cell 57, 662-673, doi: 10. 1016/j. molcel. 2014. 12. 023 (2015).